Which has better earnings & valuation, DXCM or HQY?

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.97B 6.31 $836.30M $2.53 32.82 HealthEquity $1.36B 5.85 $215.20M $2.77 34.75

Is DXCM or HQY more profitable?

DexCom has a net margin of 20.12% compared to HealthEquity's net margin of 17.36%. DexCom's return on equity of 35.94% beat HealthEquity's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% HealthEquity 17.36% 15.33% 9.51%

Does the media favor DXCM or HQY?

In the previous week, DexCom had 7 more articles in the media than HealthEquity. MarketBeat recorded 14 mentions for DexCom and 7 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.04 beat DexCom's score of 0.89 indicating that HealthEquity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthEquity 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, DXCM or PODD?

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.97B 6.31 $836.30M $2.53 32.82 Insulet $3.05B 3.00 $247.10M $5.35 24.67

Is DXCM or PODD more profitable?

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 20.12% 35.94% 14.75% Insulet 12.29% 29.29% 13.31%

Does the media refer more to DXCM or PODD?

In the previous week, Insulet had 1 more articles in the media than DexCom. MarketBeat recorded 15 mentions for Insulet and 14 mentions for DexCom. Insulet's average media sentiment score of 1.12 beat DexCom's score of 0.89 indicating that Insulet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, DXCM or ABT?

Abbott Laboratories has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.97B 6.31 $836.30M $2.53 32.82 Abbott Laboratories $46.59B 3.79 $6.52B $3.09 33.03

Does the media refer more to DXCM or ABT?

In the previous week, Abbott Laboratories had 27 more articles in the media than DexCom. MarketBeat recorded 41 mentions for Abbott Laboratories and 14 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.37 beat DexCom's score of 0.89 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abbott Laboratories 34 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer AMN or DXCM?

In the previous week, DexCom had 11 more articles in the media than AMN Healthcare Services. MarketBeat recorded 14 mentions for DexCom and 3 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.92 beat DexCom's score of 0.89 indicating that AMN Healthcare Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ITGR or DXCM?

DexCom has higher revenue and earnings than Integer. DexCom is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 2.31 $102.81M $3.66 34.44 DexCom $4.97B 6.31 $836.30M $2.53 32.82

Is ITGR or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Integer's net margin of 6.97%. DexCom's return on equity of 35.94% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% DexCom 20.12% 35.94% 14.75%

Does the media prefer ITGR or DXCM?

In the previous week, DexCom had 7 more articles in the media than Integer. MarketBeat recorded 14 mentions for DexCom and 7 mentions for Integer. DexCom's average media sentiment score of 0.89 beat Integer's score of 0.20 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DexCom (DXCM) Competitors

$83.03 -1.48 (-1.75%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$83.72 +0.69 (+0.84%)

As of 09/11/2026 07:39 PM Eastern

Compare

DXCM vs. HQY, PODD, ABT, AMN, and ITGR

Should you buy DexCom stock or one of its competitors? DexCom's main competitors and comparable companies include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), and Integer (ITGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does DexCom compare to HealthEquity?

DexCom (NASDAQ:DXCM) and HealthEquity (NASDAQ:HQY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82
HealthEquity	$1.36B	5.85	$215.20M	$2.77	34.75

DexCom presently has a consensus target price of $88.71, indicating a potential upside of 6.84%. HealthEquity has a consensus target price of $111.87, indicating a potential upside of 16.21%. Given HealthEquity's higher probable upside, analysts plainly believe HealthEquity is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

DexCom has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, HealthEquity has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

DexCom has a net margin of 20.12% compared to HealthEquity's net margin of 17.36%. DexCom's return on equity of 35.94% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
HealthEquity	17.36%	15.33%	9.51%

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.6% of HealthEquity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, DexCom had 7 more articles in the media than HealthEquity. MarketBeat recorded 14 mentions for DexCom and 7 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.04 beat DexCom's score of 0.89 indicating that HealthEquity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthEquity	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats HealthEquity on 11 of the 17 factors compared between the two stocks.

How does DexCom compare to Insulet?

DexCom (NASDAQ:DXCM) and Insulet (NASDAQ:PODD) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

DexCom has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Insulet has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82
Insulet	$3.05B	3.00	$247.10M	$5.35	24.67

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Insulet	12.29%	29.29%	13.31%

97.8% of DexCom shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DexCom presently has a consensus price target of $88.71, indicating a potential upside of 6.84%. Insulet has a consensus price target of $195.40, indicating a potential upside of 48.08%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Insulet had 1 more articles in the media than DexCom. MarketBeat recorded 15 mentions for Insulet and 14 mentions for DexCom. Insulet's average media sentiment score of 1.12 beat DexCom's score of 0.89 indicating that Insulet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats Insulet on 12 of the 17 factors compared between the two stocks.

How does DexCom compare to Abbott Laboratories?

DexCom (NASDAQ:DXCM) and Abbott Laboratories (NYSE:ABT) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

DexCom has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

97.8% of DexCom shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Abbott Laboratories had 27 more articles in the media than DexCom. MarketBeat recorded 41 mentions for Abbott Laboratories and 14 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.37 beat DexCom's score of 0.89 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	34 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Abbott Laboratories has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82
Abbott Laboratories	$46.59B	3.79	$6.52B	$3.09	33.03

DexCom currently has a consensus target price of $88.71, indicating a potential upside of 6.84%. Abbott Laboratories has a consensus target price of $119.50, indicating a potential upside of 17.07%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	20 Buy rating(s)	3 Strong Buy rating(s)	2.96

DexCom has a net margin of 20.12% compared to Abbott Laboratories' net margin of 11.65%. DexCom's return on equity of 35.94% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
Abbott Laboratories	11.65%	17.69%	9.44%

Summary

Abbott Laboratories beats DexCom on 10 of the 17 factors compared between the two stocks.

How does DexCom compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

DexCom has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$3.43B	0.38	-$95.70M	$2.68	12.44
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82

In the previous week, DexCom had 11 more articles in the media than AMN Healthcare Services. MarketBeat recorded 14 mentions for DexCom and 3 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.92 beat DexCom's score of 0.89 indicating that AMN Healthcare Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, DexCom has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

AMN Healthcare Services presently has a consensus price target of $36.00, suggesting a potential upside of 8.02%. DexCom has a consensus price target of $88.71, suggesting a potential upside of 6.84%. Given AMN Healthcare Services' higher probable upside, analysts plainly believe AMN Healthcare Services is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92

DexCom has a net margin of 20.12% compared to AMN Healthcare Services' net margin of 3.06%. DexCom's return on equity of 35.94% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	3.06%	19.92%	5.93%
DexCom	20.12%	35.94%	14.75%

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

DexCom beats AMN Healthcare Services on 12 of the 17 factors compared between the two stocks.

How does DexCom compare to Integer?

Integer (NYSE:ITGR) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

DexCom has higher revenue and earnings than Integer. DexCom is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.31	$102.81M	$3.66	34.44
DexCom	$4.97B	6.31	$836.30M	$2.53	32.82

In the previous week, DexCom had 7 more articles in the media than Integer. MarketBeat recorded 14 mentions for DexCom and 7 mentions for Integer. DexCom's average media sentiment score of 0.89 beat Integer's score of 0.20 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Integer shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of Integer shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Integer currently has a consensus target price of $109.86, suggesting a potential downside of 12.86%. DexCom has a consensus target price of $88.71, suggesting a potential upside of 6.84%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
DexCom	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.92

Integer has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, DexCom has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

DexCom has a net margin of 20.12% compared to Integer's net margin of 6.97%. DexCom's return on equity of 35.94% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
DexCom	20.12%	35.94%	14.75%

Summary

DexCom beats Integer on 13 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXCM vs. The Competition

Export

Metric	DexCom	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.89B	$5.38B	$7.13B	$12.72B
Dividend Yield	N/A	1.79%	2.56%	11.15%
P/E Ratio	32.82	25.09	275.24	25.29
Price / Sales	6.31	82.90	656.02	98.94
Price / Cash	30.52	32.53	77.04	51.44
Price / Book	11.79	5.97	10.33	6.20
Net Income	$836.30M	$150.75M	$3.50B	$358.50M
7 Day Performance	-5.54%	-2.83%	-3.32%	-2.35%
1 Month Performance	-8.56%	-3.09%	-0.41%	-2.77%
1 Year Performance	8.93%	9.34%	19.21%	7.63%

DexCom Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXCM DexCom	3.4517 of 5 stars	$83.03 -1.8%	$88.71 +6.8%	+9.3%	$31.89B	$4.97B	32.82	11,000
HQY HealthEquity	4.2682 of 5 stars	$96.07 flat	$111.87 +16.4%	+4.2%	$7.95B	$1.31B	34.68	2,814	Positive News
PODD Insulet	4.2314 of 5 stars	$147.48 flat	$195.40 +32.5%	-61.0%	$10.23B	$2.71B	27.57	5,400	Positive News
ABT Abbott Laboratories	4.8403 of 5 stars	$108.29 0.0%	$119.50 +10.4%	-23.0%	$187.38B	$44.33B	35.05	115,000	Positive News Analyst Forecast
AMN AMN Healthcare Services	2.1516 of 5 stars	$33.80 flat	$31.43 -7.0%	+76.1%	$1.31B	$2.73B	12.61	2,664	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXCM) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Competitors